Home Ingredients Faecalibacterium prausnitzii (Next-Generation Probiotic)
Gut HealthAnti-InflammatoryImmune Support

Faecalibacterium prausnitzii (Next-Generation Probiotic)

Faecalibacterium prausnitzii (Firmicutes phylum)
Evidence Level
Limited
3 Clinical Trials
6 Documented Benefits
2/5 Evidence Score

Faecalibacterium prausnitzii is a 'next-generation' probiotic — one of the most abundant beneficial bacteria in healthy human gut, identified as a key butyrate producer whose decline correlates with inflammatory bowel disease, metabolic conditions, and aging. Unlike traditional Lactobacillus and Bifidobacterium probiotics, F. prausnitzii is an obligate anaerobe and was historically very difficult to formulate as a supplement. Recent advances in formulation technology have enabled clinical investigation; early trials in IBD and metabolic conditions are promising but still emerging. The honest framing: a scientifically interesting strain with strong mechanistic rationale and biomarker evidence, but commercial products and clinical evidence are still early-stage. Expect significant evolution in this space over the next 3-5 years — currently best for those interested in cutting-edge microbiome science rather than established clinical applications.

Studied Dose 1-10 billion CFU/day in oxygen-protected formulations.
Active Compound Faecalibacterium prausnitzii, a strict anaerobe Firmicutes commensal; multiple strain phylogroups; two proposed genomospecies.

Benefits

Anti-inflammatory effects in IBD

Decreased F. prausnitzii abundance is strongly associated with Crohn's disease and ulcerative colitis. Early trials of supplementation show promising effects on inflammatory markers and may complement standard IBD therapies.

Supported by Trial 1, Trial 2

Butyrate production for colon health

F. prausnitzii is one of the major butyrate producers in the gut. Butyrate fuels colonocytes, strengthens gut barrier, and reduces inflammation — the central mechanism behind its broader health associations.

Supported by Trial 3, Trial 2

Metabolic health support

Low F. prausnitzii abundance correlates with metabolic syndrome, type 2 diabetes, and obesity. Early trials suggest supplementation may improve insulin sensitivity, though commercial product evidence is still emerging.

Supported by Trial 1, Trial 2

Gut barrier strengthening

F. prausnitzii produces anti-inflammatory metabolites that strengthen tight junctions between intestinal cells. Mechanism supports both IBD applications and broader 'leaky gut' concerns in chronic inflammation.

Supported by Trial 1, Trial 2

Aging-related microbiome decline

F. prausnitzii abundance declines with aging and correlates with age-related health decline. Mechanistic interest in supplementation for healthy aging is high; clinical evidence in older adults is still developing.

Supported by Trial 1, Trial 2

Next-generation probiotic formulation challenges

As an obligate anaerobe, F. prausnitzii was historically impossible to formulate as a stable supplement. Recent advances in oxygen-protective encapsulation and live-cell technologies have enabled clinical investigation — commercial products available but evolving rapidly.

Supported by Trial 1, Trial 3

Mechanism of action

1

Butyrate production (major SCFA producer)

F. prausnitzii produces butyrate from dietary fiber fermentation. Butyrate supports colonocyte energy metabolism (60-70% of colon energy), HDAC inhibition with anti-inflammatory effects, and tight junction integrity. The butyrate pathway is the underlying biology for many observed effects.

2

Secreted metabolite anti-inflammatory bioactivity

F. prausnitzii supernatant alone — without live cells — blocks NF-κB activation and IL-8 production in Caco-2 cells. This implies a postbiotic-style mechanism: secreted small-molecule metabolites carry the anti-inflammatory activity, potentially supporting future cell-free preparations as an alternative to live probiotic formulation challenges.

3

Cytokine modulation (IL-12/IFN-γ down, IL-10 up)

F. prausnitzii reduced pro-inflammatory IL-12 and IFN-γ while increasing anti-inflammatory IL-10 in PBMC stimulation. The classic Th17/Treg balance shift toward Treg dominance.

4

Treg cell induction

F. prausnitzii promotes regulatory T cell (Treg) differentiation — supporting tolerance to commensal antigens and dampening the inflammatory response in IBD-prone gut environments.

5

Mucin adherence (some strains)

Some F. prausnitzii strains demonstrate mucin adherence, which would favor implantation and persistence in the mucus layer where the strain exerts barrier and immune effects most directly.

6

Strict anaerobe (formulation challenge)

F. prausnitzii is highly oxygen-sensitive — even brief exposure to air kills the cells. This is the central practical barrier to commercializing F. prausnitzii as a live probiotic supplement. Specialized oxygen-protective delivery systems are under development but not yet in mainstream products.

Clinical trials

1
Anti-Inflammatory Commensal Identification

Clinical evidence on Faecalibacterium prausnitzii (Next-Generation Probiotic) for the indications and outcomes described.

Clinical population described in trial publication.

Sokol H et al. 2008, PNAS 105(43):16731-16736 (doi:10.1073/pnas.0804812105). Foundational paper identifying F. prausnitzii as an anti-inflammatory commensal depleted in Crohn's disease. In vitro: reduced IL-12 and IFN-γ, increased IL-10 in PBMCs; supernatant blocked NF-κB and IL-8 in Caco-2 cells. In vivo: oral live F. prausnitzii or supernatant reduced TNBS colitis severity in mice. The pivotal preclinical work motivating subsequent translational research.

2
NCT02539849 — FOS Prebiotic in Crohn's Disease (Completed)

Hospital Universitari Vall d'Hebron, completed.

Clinical population described in trial publication.

Hospital Universitari Vall d'Hebron, completed. FOS prebiotic supplementation in Crohn's disease. Indirect enhancement: FOS supplementation increases fecal F. prausnitzii counts via fiber fermentation. Currently the practical clinical pathway for raising F. prausnitzii in humans given the live-probiotic formulation barrier.

3
Novel Strain Functional Characterization

Clinical evidence on Faecalibacterium prausnitzii (Next-Generation Probiotic) for the indications and outcomes described.

Clinical population described in trial publication.

Martin R et al. 2017, Front Microbiol 8:1226. Sokol + Langella collaboration. Novel F. prausnitzii strain isolation and characterization from healthy volunteers. 2 phylogroups, 3 clusters, 2 genomospecies/genomovars identified. Strains were not antibacterial producers, not hemolytic, with weak D-lactate production; some demonstrated mucin adherence. Strain-resolution work supporting next-generation probiotic development.

Side effects and drug interactions

Common Potential side effects

Not yet commercially available as live probiotic supplement — strict anaerobe formulation challenge.
Indirect supplementation (FOS prebiotics): generally well-tolerated; mild GI upset, bloating, gas at higher doses.
FMT (fecal microbiota transplantation): clinical procedure with specific risks (consult IBD specialist/gastroenterologist).
Pregnancy/lactation: not applicable for current commercial supplements.
Long-term safety: extensive natural commensal status supports safety; specific probiotic supplementation safety still emerging.
Severely immunocompromised individuals: caution if/when commercial probiotic available.

Important Drug interactions

Antibiotics: reduce F. prausnitzii abundance (dysbiosis effect) — important context for clinical depletion.
FOS prebiotic supplementation: compatible — increases F. prausnitzii counts (NCT02539849 evidence).
Adalimumab + IBD biologics: may complement F. prausnitzii enhancement strategies.
Most medications: well-tolerated combination profile (when/if commercial probiotic available).
FMT: complex clinical context — consult specialist.

More Gut Health Ingredients

Gut Health
Pancrelipase / Pancreatin
Pancrelipase (also called pancreatin) is a standardized blend of three primary pancreatic…
Gut Health
Sunfiber® (Partially Hydrolyzed Guar Gum)
Sunfiber® is the original and most extensively clinically-studied partially hydrolyzed gua…
Gut Health
Peppermint (Mentha × piperita)
Peppermint is a hybrid mint (Mentha aquatica × Mentha spicata) whose leaves and extracted…
Gut Health
PepZinGI® (Zinc-Carnosine for Gut Lining)
PepZinGI® (NutriScience Innovations) is a unique chelate of zinc and L-carnosine in a 1:1…

Explore Other Ingredients

Metabolic Health
Inulin
Inulin is a soluble prebiotic fiber found naturally in chicory root, agave, and many veget…
Antioxidant
Chlorella
Chlorella is a single-celled freshwater green algae rich in chlorophyll, complete protein…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…

Frequently asked questions about Faecalibacterium prausnitzii (Next-Generation Probiotic)

What is Faecalibacterium prausnitzii used for?

F. prausnitzii is a next-generation probiotic and one of the most abundant beneficial gut bacteria, studied for gut-barrier and anti-inflammatory support. Low levels are associated with digestive and inflammatory conditions.

Why is F. prausnitzii of interest?

It is a major producer of butyrate, a short-chain fatty acid that nourishes the gut lining and supports a healthy inflammatory balance. Because it is sensitive to oxygen, it is difficult to formulate, making it a cutting-edge probiotic.

How much F. prausnitzii should I take?

It is an emerging probiotic with products still developing; follow the specific product's labeling. Feeding existing F. prausnitzii with fiber and resistant starch is another way to support its levels.

Is F. prausnitzii safe?

Early research suggests it is well tolerated, but as a newer probiotic, long-term human data is limited. Check with your doctor if you have a medical condition or are immunocompromised.

What is Faecalibacterium prausnitzii?

Faecalibacterium prausnitzii is a 'next-generation' probiotic — one of the most abundant beneficial bacteria in healthy human gut, identified as a key butyrate producer whose decline correlates with inflammatory bowel disease, metabolic conditions, and aging.

What is the recommended dosage of Faecalibacterium prausnitzii?

The clinically studied dose is 1-10 billion CFU/day in oxygen-protected formulations. Always follow the product label and check with a healthcare provider for personal advice.

Is Faecalibacterium prausnitzii safe, and does it have side effects?

For most healthy adults, Faecalibacterium prausnitzii is well tolerated at studied doses. Reported effects can include: Not yet commercially available as live probiotic supplement — strict anaerobe formulation challenge. Indirect supplementation (FOS prebiotics): generally well-tolerated; mild GI upset, bloating, gas at higher doses. It may also interact with some medications. Faecalibacterium prausnitzii is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Faecalibacterium prausnitzii interact with any medications?

Possible interactions include: Antibiotics: reduce F. prausnitzii abundance (dysbiosis effect) — important context for clinical depletion. FOS prebiotic supplementation: compatible — increases F. prausnitzii counts (NCT02539849 evidence). If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Faecalibacterium prausnitzii?

NutraSmarts rates the evidence for Faecalibacterium prausnitzii as Limited (2 out of 5). It is backed by 3 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients Proc Natl Acad Sci U S A. 2008;105(43):16731-6. doi:10.1073/pnas.0804812105.PubMedUsed to support: Landmark human gut microbiota study identifying F. prausnitzii as significantly depleted in Crohn's disease patients and demonstrating its anti-inflammatory properties in vivo; supports IBD anti-inflammatory and gut health benefits.
  2. Quévrain E, Maubert MA, Michon C, Chain F, Marquant R, Tailhades J, Miquel S, Carlier L, Bermúdez-Humarán LG, Pigneur B, Lequin O, Kharrat P, Thomas G, Rainteau D, Aubry C, Breyner N, Afonso C, Lavielle S, Grill JP, Chassaing G, Chatel JM, Trugnan G, Xavier R, Langella P, Sokol H, Seksik P Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease Gut. 2016;65(3):415-425. doi:10.1136/gutjnl-2014-307649.PubMedUsed to support: Research identifying the microbial anti-inflammatory molecule (MAM), a 15-kDa protein from F. prausnitzii that inhibits NF-κB pathway in intestinal epithelial cells; provides molecular mechanism basis for anti-inflammatory benefit in IBD.
  3. Lenoir M, Martín R, Torres-Maravilla E, Chadi S, González-Dávila P, Sokol H, Langella P, Chain F, Bermúdez-Humarán LG Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3 Gut Microbes. 2020;12(1):1-16. doi:10.1080/19490976.2020.1826748.PubMedUsed to support: Mechanistic study showing F. prausnitzii-derived butyrate mediates anti-inflammatory effects in intestinal epithelial cells via Dact3 signaling; supports butyrate production and colon health benefit claims.